after giving informed consent you receive a participant identification number.

baseline data are collected, including medical history, current medications, and basic health measurements.

a series of examinations are performed before any study medication is taken.

these include blood and urine laboratory tests, a 12‑lead electrocardiogram (ecg) to check heart rhythm, measurement of blood pressure, pulse, body weight, and cognitive tests such as the mini‑mental state examination (mmse) and other questionnaires that evaluate hallucinations, delusions, and overall functioning.

you begin taking fesoterodine, an oral tablet containing 210 mg of the active substance.

the tablet is taken by mouth as directed by the study staff and is continued for the duration of the long‑term safety period of the trial.

scheduled visits occur at regular intervals (for example, monthly) throughout the study.

at each visit blood and urine samples are collected again, an ecg may be repeated, vital signs and body weight are measured, and the same questionnaires used at baseline are administered to monitor any changes.

the study medication is dispensed for the next interval and any missed doses are recorded.

any new health problems that arise after the medication is started are recorded as treatment‑emergent adverse events (adverse events that appear during the study).

serious adverse events that require medical attention are also documented, and the study team decides whether the medication should be continued or stopped based on these findings.

after the planned study period ends, a final set of assessments identical to the baseline examinations is performed.

the study medication is discontinued, and a summary of safety and tolerability findings is compiled.